Voyager Therapeutics, Inc. (VYGR)
NASDAQ: VYGR · Real-Time Price · USD
3.480
+0.040 (1.16%)
Aug 25, 2026, 4:00 PM EDT - Market closed
Voyager Therapeutics Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| 34.46 | 40.37 | 80 | 250.01 | 40.91 | 37.42 | |
Revenue Growth | -19.07% | -49.53% | -68.00% | 511.16% | 9.33% | -78.14% |
Cost of Revenue | 116.06 | 132.27 | 124.59 | 92.17 | 55.76 | 73.79 |
Gross Profit | -81.6 | -91.9 | -44.59 | 157.84 | -14.86 | -36.37 |
Selling, General & Admin | 32.09 | 36.44 | 35.92 | 35.82 | 30.98 | 37.25 |
Operating Expenses | 32.09 | 36.44 | 35.92 | 35.82 | 30.98 | 37.25 |
Operating Income | -113.69 | -128.34 | -80.51 | 122.01 | -45.84 | -73.62 |
Interest Expense | - | - | - | - | - | -0.39 |
Interest & Investment Income | 7.94 | 10.62 | 18.33 | 11.72 | 1.79 | - |
Other Non Operating Income (Expenses) | 1.65 | 1.65 | 0.62 | 0 | 2.65 | - |
EBT Excluding Unusual Items | -104.1 | -116.08 | -61.56 | 133.74 | -41.39 | -74.01 |
Merger & Restructuring Charges | -3.5 | -3.5 | - | - | - | - |
Gain (Loss) on Sale of Investments | - | - | - | - | - | 2.81 |
Asset Writedown | - | - | -2.78 | - | - | - |
Other Unusual Items | - | - | - | - | -5 | - |
Pretax Income | -107.6 | -119.58 | -64.34 | 133.74 | -46.39 | -71.2 |
Income Tax Expense | 0.13 | 0.14 | 0.67 | 1.41 | 0.02 | - |
Net Income | -107.73 | -119.72 | -65 | 132.33 | -46.41 | -71.2 |
Net Income to Common | -107.73 | -119.72 | -65 | 132.33 | -46.41 | -71.2 |
Net Income Growth | - | - | - | - | - | - |
Shares Outstanding (Basic) | 59 | 59 | 58 | 43 | 38 | 38 |
Shares Outstanding (Diluted) | 59 | 59 | 58 | 45 | 38 | 38 |
Shares Change | 2.13% | 1.77% | 29.39% | 16.20% | 1.83% | 0.86% |
EPS (Basic) | -1.81 | -2.04 | -1.13 | 3.08 | -1.21 | -1.89 |
EPS (Diluted) | -1.81 | -2.04 | -1.13 | 2.97 | -1.21 | -1.89 |
EPS Growth | - | - | - | - | - | - |
Additional Metrics
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Free Cash Flow | -121.42 | -135.06 | -18.83 | 74.66 | -15 | -55.13 |
Free Cash Flow Per Share | -2.04 | -2.30 | -0.33 | 1.68 | -0.39 | -1.46 |
Gross Margin | -236.81% | -227.62% | -55.74% | 63.13% | -36.32% | -97.21% |
Operating Margin | -329.92% | -317.89% | -100.64% | 48.80% | -112.05% | -196.76% |
Profit Margin | -312.63% | -296.53% | -81.25% | 52.93% | -113.45% | -190.29% |
Free Cash Flow Margin | -352.36% | -334.53% | -23.54% | 29.86% | -36.67% | -147.36% |
EBITDA | -109.87 | -124.28 | -75.78 | 126.46 | -39.65 | -68.45 |
EBITDA Margin | - | - | -94.72% | 50.58% | -96.92% | -182.96% |
D&A For EBITDA | 3.82 | 4.06 | 4.73 | 4.44 | 6.19 | 5.17 |
EBIT | -113.69 | -128.34 | -80.51 | 122.01 | -45.84 | -73.62 |
EBIT Margin | - | - | -100.64% | 48.80% | -112.05% | -196.76% |
Effective Tax Rate | - | - | - | 1.05% | - | - |